Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Malignant fibrous histiocytomas are well-described tumors of the soft tissues. Recent investigations have shown that malignant histiocytoma may also occur as a primary bone tumor. However, difficulties may arise to distinguish malignant histiocytoma of bone from other malignant bone tumors, such as
osteosarcoma
. In the present study, the ultrastructure of five cases of malignant fibrous histiocytoma of bone is compared with that of
osteosarcoma
. The results show that malignant fibrous histiocytoma is composed mainly of histiocytic cells and fibroblastic cells. In addition, xanthomatous cells, undifferentiated cells, and giant cells may be observed. By contrast, the predominant cell type in
osteosarcoma
is the neoplastic osteoblast, characterized by abundant rough endoplasmic reticulum. Signs of matrix calcification in the intercellular matrix between the collagen fibrils are regularly observed in
osteosarcoma
, but not in malignant histiocytoma. From these results it is concluded that the ultrastructure of malignant fibrous histiocytoma arising in bone is morphologically identical with the soft tissue counterpart of this tumor. The components of the tumor are derived from neoplastic histiocytes. This cytogenesis differs from that of
osteosarcoma
, which is derived from neoplastic osteoblasts. Therefore, from the ultrastructural point of view, malignant fibrous histiocytoma of bone should be accepted as a distinct histologic entity among bone tumors.
...
PMID:Malignant fibrous histiocytoma of bone and osteosarcoma. A comparative light and electron microscopic study. 22 75
A mixed malignant tumour of the lung intermediate in type between pulmonary blastoma and carcinosarcoma is described. The epithelial component consisted of squamous carcinoma, undifferentiated carcinoma, and clefts lined by bland epithelial cells. The supporting stroma was composed of pleomorphic sarcoma, fibrosarcoma, chondrosarcoma,
osteosarcoma
, and indeterminate mesenchymal tissue. The tumour was removed surgically, but the patient died postoperatively with rapidly developing multiple bony and soft tissue metastases. Subcutaneous metastases showed the appearnce of poorly differentiated pleomorphic sarcoma. Published reports of mixed malignant lung tumours are reviewed.
...
PMID:Mixed malignant tumour of the lung. 22 82
Eleven cases of sarcoma in Paget's disease of bone are presented, together with an extensive review of the literature. These neoplasms are rare but not exceptional, and mostly affect male subjects in the seventh decade of life. The sites most frequently affected are the pelvis, femur and humerus. In 30 per cent of cases these neoplasms are multifocal. Radiographically the lesions are nearly always osteolytic. The radiographic diagnosis may, however, be quite difficult, especially in the presence of the severe (but benign) osteolyic lesions that sometimes occur in Paget's disease. Morphologically these tumours are mostly highly polymorphic sarcomas. The cases in this series were diagnosed histologically as
osteosarcoma
, grade 3 fibrosarcoma, and malignant fibrous histiocytoma; but there are no prognostic differences between the various histological types. The prognosis is very serious, only about 3 per cent of patients surviving for five years from the time of diagnosis. Therapy, unfortunately nearly always palliative, is based on amputation or disarticulation after sections biopsy in cases where the disease is localised to the limbs, and on radiotherapy in cases not amenable to surgery.
...
PMID:Sarcoma in Paget's disease (11 cases). 23 74
Transplanted syngeneic osteosarcomas (induced by 32P in DA rats) grew significantly larger in DA rats receiving a simultaneous transplant of allogeneic
osteosarcoma
than in rats receiving syngeneic tumour only (P less than 0-01). Two other malignant allogeneic tumours, and allogeneic spleen cells, did not alter the growth of the transplanted syngeneic osteosarcomas. When the allogeneic
osteosarcoma
was given 7 days before the syngeneic tumour, the reverse effect (retardation) occurred. When given 7 days after the syngeneic tumour cells, the effect on both syngeneic and allogeneic tumour growth was variable. Some possible reasons for these findings are discussed, and the argument is presented that immunological phenonema are involved in the reaction.
...
PMID:Enhanced osteosarcoma growth produced in rats by osteosarcoma allografts. 26 82
Undiluted, fivefold-diluted, and 25-fold-diluted doses of a stock of Moloney murine sarcoma virus were injected directly, in a volume of 0.025 ml, into the backs of fetal Sprague-Dawley rats by laparotomy through the uterine wall at 18 days of gestation. During the first 8 weeks after birth the young responded to the virus with remarkably high but dose-dependent incidences of neoplasms. When a one-fifth dilution of the virus preparation was inoculated at fetal ages 16, 18, and 20 days, the incidences of lesions decreased with advancing fetal age. The tumors developed preferentially at the virus inoculation site and/or in the proximal parts of the extremeties; all were considered to be of mesenchymal derivation, i.e., malignant mesenchymoma, rhabdomyosarcoma,
osteosarcoma
, fibrosarcoma or fibromyxosarcoma, hemangiosarcoma, plasmacytoma, and a giant cell tumor. This injection procedure provided us with a valuable experimental tool for the rapid screening or testing of potential chemical carcinogens and other biologic studies.
...
PMID:Enhancement of tumor induction in rats with Moloney murine sarcoma virus by a "new" method based on direct injection into fetuses. 26 91
An 11-year-old Caucasian girl who had been cured of bilateral retinoblastoma developed non-radiation-induced
osteosarcoma
in multiple sites of the extremities. Investigation of the medical histories of 36 of her family members through six generations revealed that 8 relatives on the maternal side (22%) had malignant tumors, predominately genitourinary carcinomas, 2(6%) had benign tumors only, and 2(6%) had both benign and malignant neoplasms. The histologic variety of these tumors, the predominance of genitourinary carcinoma, the higher than expected frequency of tumor appearance over six generations, and the occurrence of malignant tumors in direct lineage suggest that the case of retinoblastoma followed by
osteosarcoma
is part of a familial cancer syndrome.
...
PMID:A new familial cancer syndrome? A spectrum of malignant and benign tumors including retinoblastoma, carcinoma of the bladder and other genitourinary tumors, thyroid adenoma, and a probable case of multifocal osteosarcoma. 26 92
Osteosarcomas
formed in antilymphocyte serum (ALS)-treated hamsters when 2x10(6) TE-85 human
osteosarcoma
cells (maintained in tissue culture) infected with M-MSV (RD-114) virus were injected adjacent to the femur or the scapula; undifferentiated sarcomas formed when 1 x 10(6) cells were injected subcutaneously. Tumors were palpable 10 to 14 days after the cells were injected and grew progressively until the animals died (mean survival time was 30 days). All animals had pulmonary metastases. Neither the subcutaneous sarcomas nor the metastases contained bone or osteoid; however, the osteosarcomas adjacent ot the femur and scapula contained collagen, osteoid and calcified bone when observed by light and electron microscopy. These results indicate that the TE-85-M-MSV cell-ALS hamster system is an animal model for the study of osteosarcomas of human cell origin.
...
PMID:An animal model for human osteosarcoma. 26 8
Osteosarcoma
cells (BFO cell line) were successfully maintained in tissue culture for 3 years. BFO cells showed 100 per cent tumorigenicity by the isologous implantation, and almost the same histological features as the original BF
osteosarcoma
. BFO cells synthesize and secrete large quantities of alkaline phosphatase both in vitro (cell culture) and in vivo (tumor bearing mice). BFO cells showed a suppression in synthesizing the osteoinductive factor in vitro, but regained the capacity to synthesize it when implanted back into an isologous host. The cells showed rapid growth, a serum requirement, and no contact inhibition. Doubling time was 8.6 hours in a logarithmic growth phase. Cell cycle analyses by pulse labeling of 3H-thymidine was performed after synchronization of the cells by double treatment with an excess thymidine.
...
PMID:Characteristics of osteosarcoma cells in culture. 26 6
New Zealand White rabbits were immunized with whole-cell suspensions of TE-85 cells (from a human
osteosarcoma
) maintained in tissue culture. RNA was extracted from the lymphoid tissues of the immunized animals. Normal human peripheral blood lymphocytes were pretreated with both the whole-cell immune RNA (IRNA) and the Sephadex column-eluted fractions of the whole-cell IRNA. Significant stimulation of the cytotoxic effect of the lymphocytes was observed following whole-cell IRNA pretreatment and pretreatment with peak III fractions eluted from the column. This increase in inhibition was observed whether the target cells were TE-85 (the immunizing cells), L.M. and M.Mc. (two unrelated
osteosarcoma
primary cell cultures), or TE-85-M-MSV cells (a cell line capable of producing a human
osteosarcoma
in immunosuppressed hamsters). No inhibition was observed when cells from other types of human tumors were used as target cells. The results suggested that the transferred immunity was directed against tumor-specific
osteosarcoma
antigens.
...
PMID:Effect of xenogeneic immune RNA on normal human lymphocytes against human osteosarcoma cells in vitro. 26 78
The dosimetry of alpha-emitting radionuclides in bone is discussed. Results are presented for average dose rates to tissues close to endosteal surfaces and to haematopoietic bone marrow from thin plane sources of radionuclides buried to different depths in bone and emitting alpha-particles with energies in the range 3-8 MeV. These results are used to demonstrate that on an activity basis 239Pu is unlikely to be more than fifteen times as toxic as 226Ra with respect to
osteosarcoma
and leukaemia induction in man.
...
PMID:Aspects of the dosimetry of alpha-emitting radionuclides in bone with particular emphasis on 226Ra and 239Pu. 26 72
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>